Pyxis Oncology to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Tom Civik to join Guggenheim Healthcare Innovation Conference fireside chat November 9
- ➤Tom Civik to join Stifel Healthcare Conference fireside chat November 10
- ➤MICVO is being evaluated in Phase 1 monotherapy study for R/M HNSCC
- ➤MICVO is being evaluated with KEYTRUDA in Phase 1/2 solid-tumor study
- ➤MICVO received FDA Fast Track Designation for certain R/M HNSCC patients
Expert Statements
Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology
“will participate in fireside chats at two upcoming conferences”
BOSTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Tom Civik, Chief Executive Officer and Chairman of Pyxis Oncology, will participate in fireside chats at two upcoming conferences. * Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA on Monday, November 9, 2026, at 9:00 a.m. ET.
* Stifel 2026 Healthcare Conference in New York, NY on Tuesday, November 10, 2026, at 4:40 p.m. ET. Live webcasts and replays of the fireside chats will be available on the Events & Presentations page in the Investor Relations section of Pyxis Oncology’s website, ir.pyxisoncology.com.
Get started
Create a free account to read the full story.